At TCT Connect, investigators presented the 30-day primary endpoint analysis of the Disrupt CAD III study, the largest and most rigorous coronary IVL study to date.
After the meeting, we invited the study’s co-PI, Dr. Jonathan Hill, and two additional CAD III investigators, Drs. Margaret McEntegart and Holger Nef, to review the results and discuss the trial takeaways with two thought leaders in calcium modification not involved in the study, Profs. Carlo Di Mario and Flavio Ribichini, to hear their take as independent physicians.
The conversation spanned many great topics, including whether imaging is necessary or a nice-to-have with IVL, the learning curve associated with the technology, the clinical impact of IVL-induced ventricular capture, and what the compelling CAD III data add to the existing coronary IVL body of evidence. We hope you enjoy the discussion!
Important Safety Information - Coronary IVL
Caution: In the United States, Shockwave C2 Coronary IVL catheters are investigational devices, limited by United States law to investigational use. DISRUPT CAD III Study
Shockwave C2 Coronary IVL catheters are commercially available in certain countries outside the U.S. Please contact your local Shockwave representative for specific country availability. The Shockwave C2 Coronary IVL catheters are indicated for lithotripsy-enhanced, low-pressure balloon dilatation of calcified, stenotic de novo coronary arteries prior to stenting. For the full IFU containing important safety information please visit: https://shockwavemedical.com/clinicians/international/coronary/shockwave-c2/